Envestnet Asset Management Inc. Sells 1,228,773 Shares of Abbott Laboratories $ABT

Key Points

• Envestnet Asset Management reduced its Abbott Laboratories stake by 23.7%, selling 1,228,773 shares and retaining 3.96 million shares valued at approximately $359 million. Institutional investors collectively own 75.18% of Abbott’s outstanding stock.
• Abbott exceeded quarterly expectations with adjusted EPS of $1.31 and revenue of $12.59 billion, while revenue increased 13% year over year. Management issued fiscal 2026 EPS guidance of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63 per share, equivalent to a 2.4% annualized yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $119.50, above the reported share price of $103.62.

Envestnet Asset Management Inc. trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 23.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,956,395 shares of the healthcare product maker's stock after selling 1,228,773 shares during the period. Envestnet Asset Management Inc. owned 0.23% of Abbott Laboratories worth $359,003,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after acquiring an additional 1,350,766 shares during the period. Premier Financial Group bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $118,000. Security National Bank of Sioux City Iowa IA lifted its holdings in Abbott Laboratories by 34.9% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 24,246 shares of the healthcare product maker's stock worth $2,200,000 after purchasing an additional 6,268 shares in the last quarter. Menlo Advisors LLC boosted its stake in Abbott Laboratories by 1.1% in the 2nd quarter. Menlo Advisors LLC now owns 67,919 shares of the healthcare product maker's stock worth $6,162,000 after purchasing an additional 723 shares during the period. Finally, Core Capital Management & Research inc. bought a new stake in shares of Abbott Laboratories during the second quarter valued at about $64,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Down 0.1%

Shares of ABT opened at $103.62 on Thursday. The firm's 50 day simple moving average is $107.15 and its 200 day simple moving average is $99.10. The company has a market capitalization of $179.31 billion, a P/E ratio of 33.53, a P/E/G ratio of 1.92 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $136.83.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories's payout ratio is 81.55%.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott and Berry Street announced an exclusive partnership combining Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered registered-dietitian and nutrition-coaching platform. The initiative could improve Lingo adoption, expand Abbott’s consumer health ecosystem and strengthen its position in metabolic-health services. Abbott and Berry Street partnership article
• Positive Sentiment: Abbott’s Volt Pulsed Field Ablation System reportedly saw its first clinical use in Canada and at an Illinois heart center for treating atrial fibrillation. Additional real-world use could support the medical-device pipeline and future cardiovascular revenue growth. Abbott digital health and formula settlement article
• Positive Sentiment: Investor commentary continues to describe Abbott as a high-quality, diversified healthcare business with attractive long-term prospects. Its exposure to diagnostics, medical devices, nutrition and digital health provides multiple growth avenues, and the therapeutic drug-monitoring market is projected to expand substantially through 2032. What makes Abbott attractive article
• Neutral Sentiment: ABT is drawing increased attention from investors and analysts. Recent results exceeded consensus estimates, with revenue growth supported by the company’s diversified portfolio, but commentary generally characterizes the shares as a strong business available at a fair—not deeply discounted—price. Abbott trending stock article
• Negative Sentiment: Abbott agreed to pay approximately $385 million to settle infant-formula litigation. Although the settlement removes some legal uncertainty, the cash cost and reputational overhang are negative for near-term sentiment. Valuation comparisons with faster-growing healthcare companies, including Exact Sciences, may also reduce enthusiasm among growth-oriented investors. Abbott and Exact Sciences comparison article

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABT. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, TD Cowen reiterated a "buy" rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.